<table>
<thead>
<tr>
<th>Title</th>
<th>Atrial Anti-Arrhythmic Effects of Heptanol in Langendorff-Perfused Mouse Hearts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Tse, G; Tse, V; Yeo, JM; Sun, B</td>
</tr>
<tr>
<td>Citation</td>
<td>PLoS One, 2016, v. 11 n. 2, p. Article no. e0148858</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2016</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/223191">http://hdl.handle.net/10722/223191</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Atrial Anti-Arrhythmic Effects of Heptanol in Langendorff-Perfused Mouse Hearts

Gary Tse¹, Vivian Tse², Jie Ming Yeo³, Bing Sun⁴*

¹ School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong S.A. R., China, ² Department of Physiology, McGill University, Montreal, Canada, ³ Faculty of Medicine, Imperial College London, London, United Kingdom, ⁴ Department of Cardiology, Tongji University Affiliated Tongji Hospital, Shanghai, China

* woowoocncn@163.com

Abstract

Acute effects of heptanol (0.1 to 2 mM) on atrial electrophysiology were explored in Langendorff-perfused mouse hearts. Left atrial bipolar electrogram or monophasic action potential recordings were obtained during right atrial stimulation. Regular pacing at 8 Hz elicited atrial activity in 11 out of 11 hearts without inducing atrial arrhythmias. Programmed electrical stimulation using a S1S2 protocol provoked atrial tachy-arrhythmias in 9 of 17 hearts. In the initially arrhythmic group, 2 mM heptanol exerted anti-arrhythmic effects (Fisher’s exact test, P < 0.05) and increased atrial effective refractory period (ERP) from 26.0 ± 1.9 to 57.1 ± 2.5 ms (ANOVA, P < 0.001) despite increasing activation latency from 18.7 ± 1.1 to 28.9 ± 2.1 ms (P < 0.001) and leaving action potential duration at 90% repolarization (APD90) unaltered (25.6 ± 1.2 vs. 27.2 ± 1.2 ms; P > 0.05), which led to increases in ERP/latency ratio from 1.4 ± 0.1 to 2.1 ± 0.2 and ERP/APD90 ratio from 1.0 ± 0.1 to 2.1 ± 0.2 (P < 0.001). In contrast, in the initially non-arrhythmic group, heptanol did not alter arrhythmogenicity, increased AERP from 47.3 ± 5.3 to 54.5 ± 3.1 ms (P < 0.05) and activation latency from 23.7 ± 2.2 to 31.3 ± 2.5 ms and did not alter APD90 (24.1 ± 1.2 vs. 25.0 ± 2.3 ms; P > 0.05), leaving both AERP/latency ratio (2.1 ± 0.3 vs. 1.9 ± 0.2; P > 0.05) and ERP/APD90 ratio (2.0 ± 0.2 vs. 2.1 ± 0.1; P > 0.05) unaltered. Lower heptanol concentrations (0.1, 0.5 and 1 mM) did not alter arrhythmogenicity or the above parameters. The present findings contrast with known ventricular pro-arrhythmic effects of heptanol associated with decreased ERP/latency ratio, despite increased ERP/APD ratio observed in both the atria and ventricles.

Introduction

The accurately timed sequence of contractile activity in different cardiac regions depends on the orderly generation and the subsequent propagation of an action potential (AP). Conduction velocity (CV) of the AP depends on sodium channel activation followed by gap junction conduction through successive myocardial regions [1–3]. Decreases in CV, which is proportional to activation latency, have been associated with increased risk of arrhythmias [4, 5]. Cardiac arrhythmias have been explored in murine models, which permit alterations in the
expression or function of ion channels using genetic or pharmacological methods [6, 7]. The resulting electrophysiological abnormalities can then be characterized using both in vivo and ex vivo techniques [8, 9].

Recently, acute, reversible ventricular arrhythmias due to CV slowing were observed using the gap junction and sodium channel inhibitor heptanol in wild-type mouse hearts [10]. The present study goes on to examine its atrial effects under similar experimental conditions, and demonstrate contrasting electrophysiological properties under both control conditions and in the presence of heptanol. Heptanol at 2 mM exerted anti-arrhythmic effects, attributable to its differing actions on activation latency, ERP and APD and their consequent scaling of ERP/latency and ERP/APD ratios, thereby implicating these parameters as critical in the determination of arrhythmogenicity.

**Materials and Methods**

All procedures described in this study complied with the UK Animals (Scientific Procedures) Act 1986. This study was approved by the Animal Welfare and Ethical Review Body at the University of Cambridge. All procedures described in this study complied with the UK Animals (Scientific Procedures) Act 1986. Both male and female wild-type mice (129 genetic background), between 5 and 7 months of age, were housed in plastic cages of an animal house facility at room temperature (21 ± 1°C) and subject to a 12:12 h light / dark cycle. The mice had access to sterile rodent chow and drinking water at all times. Krebs-Henseleit solution used in the experiments (mM: NaCl 119, NaHCO3 25, KCl 4, KH2PO4 1.2, MgCl2 1, CaCl2 1.8, glucose 10 and sodium pyruvate 2, pH 7.4) was bubbled with 95% O2−5% CO2 [11]. Heptanol (Sigma, Dorset, UK; density: 0.82 g ml−1), which is soluble in aqueous solutions up to 9 mM (The Merck Index, New Jersey, USA), was diluted using Krebs-Henseleit solution to produce final concentrations between 0.1 and 2 mM.

The Langendorff perfusion technique is an established method that has been adapted for study of cardiac electrophysiology in mice [12]. Mice were killed by cervical dislocation (Schedule 1 of the UK Animals (Scientific Procedures) Act 1986). This permitted isolation of their hearts, which were then submerged in ice-cold bicarbonate-buffered, Krebs-Henseleit solution. The surrounding lung tissue was removed, with the aorta cannulated using a tailor-made 21-gauge cannula prefilled with ice-cold buffer, secured using a micro-aneurysm clip (Harvard Apparatus, Kent, UK) and attached to the perfusion apparatus. The aorta was perfused with Krebs-Henseleit solution at a rate of 2 to 2.5 ml/min using a peristaltic pump (Watson–Marlow Bredel pumps model 505S, Cornwall, UK), passing successively through 200 μm and 5 μm filters and warmed to 37°C by water jacket and circulator. Hearts that regained their pink colour and began to contract spontaneously were studied further (approximately 90%). The remaining 10% were discarded. To minimize residual effects of endogenous release of catecholamines, the hearts were perfused with Krebs–Henseleit solution for a further 20 minutes before experimentation. The time taken for the perfusing solution to reach the heart from the buffer reservoir was determined from a series of control experiments, which involved the addition of a coloured solution to a colourless Krebs–Henseleit solution and measurement of the time taken for the discarded solution to gain coloration. This procedure was repeated twice and the mean duration was calculated. Hearts were studied for similar durations of heptanol exposure, which were 360 ± 51 s, 314 ± 32 s, 312 ± 54 s and 380 ± 56 s for 0.1 mM, 0.5 mM, 1 mM and 2 mM heptanol, respectively (n = 11). Because of the known time-dependent effects of heptanol in the ventricles [10], the electrophysiological parameters were consistently analyzed after a standardized time point which was taken to be 120 seconds after its introduction.
Electrical stimulation of the right atrial epicardium was achieved using paired platinum electrodes (1 mm inter-pole distance). Regular pacing was set at 8 Hz (i.e. basic cycle length, (BCL), of 125 ms), using 2 ms duration, square-wave stimuli applied at three times the excitation threshold (Grass S48 Stimulator, Grass-Telefactor, Berkshire, UK), allowing direct comparison with previous mouse studies of atrial and ventricular arrhythmogenesis [10, 13, 14].

Programmed electrical stimulation (PES) imposed drive trains of eight paced S1 stimuli delivered at a 125 ms BCL, followed by premature S2 extra-stimuli every ninth stimulus. S1S2 intervals first equaled the pacing interval and were then successively reduced by 1 ms with each stimulus cycle, until the atrial effective refractory period (AERP) was reached or arrhythmic activity was provoked. PES was applied twice before application of the test agent. It was then applied at standardized time points of 120 seconds after its application, because of its known time-dependent effects on activation latency and ERP in the ventricles [10]. This duration was sufficient for the actions of heptanol to take place, as previously shown. PES was applied 15 minutes after its removal from the perfusing solution to allow reversibility of heptanol to be studied. In between PES procedures hearts were regularly paced at 8 Hz.

Bipolar electrograms (BEGs) were recorded from the left atrial epicardium using a paired (1 mm inter-pole spacing) platinum electrode. Monophasic action potentials (MAPs) were also recorded from the left ventricular epicardium using a MAP electrode (Linton Instruments, Kent, UK). Such simultaneous recordings permitted atrial activity to be distinguished from ventricular far-field activity at the atrial recording electrode. The BEG signals were pre-amplified (NL100AK head stage), amplified (NL 104A amplifier) and filtered (band-pass between 30 Hz and 1 kHz) using a NL125/6 filter (Neurolog, Hertfordshire, UK) and then digitized using an analogue-to-digital converter (1401plus MKII, Cambridge Electronic Design, Cambridgeshire, UK) at 5 kHz. For atrial MAP recordings, the atrio-ventricular nodes of the Langendorff perfused hearts were first mechanically ablated as previously described [13, 14]. This eliminated ventricular far-field activity at the recording electrode. MAPs were recorded from the left atrial epicardium during regular 8 Hz stimulation to exclude rate-dependent differences in action potential durations (APDs). All MAPs were pre-amplified, amplified and band-pass filtered between 0.5 Hz and 1 kHz and then digitized at 5 kHz. The waveforms were then analysed using Spike2 software (Cambridge Electronic Design, Cambridgeshire, UK). MAP waveforms not matching the criteria for MAP signals of a stable baseline, fast upstroke without inflection or negative spike and rapid first phase of repolarization were rejected [15]. 0% repolarization was measured at the peak of the MAP and 100% repolarization was measured at the point of return of the membrane potential to baseline [15–17].

The following atrial electrophysiological parameters were derived from the experimental recordings:

1. activation latency, defined as the time difference between the stimulus artefact and the first deflection of the BEG;
2. AERP, defined as the longest S1S2 interval at which the S2 extra-stimulus failed to initiate an atrial signal during PES;
3. APDx, defined as the time taken for the recorded voltage to decline from the peak of the MAP to x% repolarization;
4. AERP/latency ratio and (6) AERP/APD90 ratio.

All experimental values obtained are given as mean ± standard error of the mean (SEM). Comparisons between different experimental groups were carried out by one-way analysis of variance (ANOVA) followed by Tukey’s Honestly Significant Difference test, and Student’s t-test as appropriate. Categorical data were compared with Fisher’s exact test (two-tailed). $P < 0.05$ was considered statistically significant in all cases. $P < 0.05$, $P < 0.01$ and $P < 0.001$ were denoted by *, ** and ***, respectively.
Results

The present experiments investigated the effects of the gap junction and sodium channel inhibitor heptanol (0.1, 0.5, 1 or 2 mM) on atrial arrhythmic and electrophysiological properties in Langendorff-perfused mouse hearts, complementing a previous report describing its ventricular pro-arrhythmic effects [10].

Heptanol (2 mM) slows conduction without inducing atrial arrhythmic activity during regular pacing

The initial experiments were conducted during regular pacing at 8 Hz, close to the mouse in vivo heart rate [18]. The hearts were exposed to Krebs-Henseleit solution (KHS) for 20 min, treated with 2 mM heptanol/KHS for at least 5 min, then returned to KHS alone for 15 min. Simultaneous bipolar electrogram (BEG) and monophasic action potential (MAP) recordings were obtained from the left atrial and the left ventricular epicardium, respectively, during this procedure (Fig 1a to 1c). Signals from atrial events were identified by deflections present in the BEG but absent from the MAP recordings, whereas those from ventricular events were identified by deflections present in both the BEG and MAP recordings (labelled “A” and “V”, respectively). It was therefore possible to distinguish atrial activity from ventricular far-field activity at the atrial recording electrode.

Regular atrial activity was observed before introduction of the test agent. Heptanol (2 mM) did not elicit any arrhythmic activity in the atria, despite gradually increasing activation latency from 20.2 ± 1.0 ms to 32.2 ± 2.7 ms (Fig 1d; asterisks, ANOVA, \( P < 0.001 \)) over 120 seconds after its introduction (\( n = 11 \)). Withdrawal of heptanol restored activation latency to 20.7 ± 1.3 ms, which were indistinguishable from control values (\( P > 0.05 \)).

A subset of control hearts shows inducible atrial tachy-arrhythmias which are inhibited by heptanol (2 mM)

The subsequent experiments examined the incidences of inducible arrhythmias using PES procedures under the same pharmacological conditions as above. This identified a subset of the hearts showing episodes of atrial tachy-arrhythmias (Fig 2a, top panel). These arrhythmic phenomena were inhibited by heptanol (2 mM) (Fig 2a, middle panel), but subsequently reappeared after its removal from the perfusing solution (Fig 2a, bottom panel). The remaining hearts did not show evidence of atrial arrhythmias under control conditions (Fig 2b, top panel), and remained non-arrhythmic both after application (Fig 2b, middle panel) and withdrawal of heptanol (2 mM) from the perfusing solution (Fig 2b, bottom panel). In both the arrhythmic and non-arrhythmic groups, heptanol (2 mM) produced second degree atrioventricular block (AVB), which rapidly progressed to third degree AVB. The incidences of atrial arrhythmias are summarized in Fig 2c: 9 out of 17 hearts were arrhythmic under control conditions and all 9 were rendered non-arrhythmic by heptanol (2 mM) (Fisher’s exact test, \( P < 0.001 \)). Atrial tachy-arrhythmias reappeared in 7 of these hearts after its withdrawal from the perfusing solution (Fisher’s exact test, \( P < 0.001 \)). Finally, atrial MAP recordings were obtained during 8 Hz pacing (Fig 3), allowing action potential durations (APDs) to be determined.

Heptanol increases activation latency and ERP without altering APD in both the arrhythmic and non-arrhythmic groups

The arrhythmic group had a mean activation latency of 18.7 ± 1.1 ms, AERP of 26.0 ± 1.9 ms and APD\(_{90}\) of 25.6 ± 1.2 ms (Fig 4a, 4b and 4c). Heptanol increased activation latency to 28.9 ± 2.1 ms (asterisks, ANOVA, \( P < 0.001 \)), and AERP to 57.1 ± 2.5 ms (asterisks, \( P < 0.001 \))
Fig 1. Simultaneous left atrial bipolar electrogram (BEG) (top trace) and left ventricular monophasic action potential (MAP) (bottom trace) recordings obtained before (a, control) and after the introduction (b) of 2 mM heptanol, and 15 minutes after its removal from the perfusing solution (c, wash out) during regular 8 Hz pacing. Atrial and ventricular deflections were labelled “A” and “V”, respectively. Activation latency (d) and CV (e) obtained before and after introduction of 2 mM heptanol, and 15 minutes after its removal (n = 11 in all cases). Activation latency was significantly increased (asterisks, ANOVA, P < 0.001) and therefore CV was significantly decreased (asterisks, P < 0.01) by 2 mM heptanol. The effects of heptanol were reversible as both activation latency and CV recovered to their control values after its removal from the perfusing solution (daggers, P > 0.05).

doi:10.1371/journal.pone.0148858.g001
without altering APD$_{90}$ (27.2 ± 1.2 ms; $P > 0.05$). Compared to the arrhythmic group, the non-arrhythmic group showed longer activation latency (Fig 4d; 23.7 ± 2.2 ms; $P < 0.05$) but longer AERP (Fig 4c; 47.3 ± 5.3 ms; $P < 0.001$) and similar APD$_{90}$ (Fig 4f; 24.1 ± 1.2 ms). In this group, heptanol (2 mM) increased activation latency to 31.3 ± 2.5 ms (asterisk, $P < 0.05$), and
Fig 3. Monophasic action potential (MAP) recordings obtained from the arrhythmic (a) and non-arrhythmic hearts (b) during regular 8 Hz pacing before (top panel) and after introduction of 2 mM heptanol (middle panel) and after its removal from the perfusing solution (bottom panel).

doi:10.1371/journal.pone.0148858.g003
Fig 4. In the arrhythmic group, 2 mM heptanol increased activation latency (a, asterisks, ANOVA, $P < 0.001$, $n = 9$) and therefore decreased the corresponding CV (b; $P < 0.01; n = 9$) and increased atrial effective refractory period (AERP) (c, $P < 0.001; n = 9$) without altering APD$_{90}$ (d, $P > 0.05, n = 9$). In the non-arrhythmic group, 2 mM heptanol also increased activation latency (e, $P < 0.05, n = 8$), decreased CV (f, $P < 0.05, n = 8$) and increased AERP (g, $P < 0.05, n = 8$) without altering APD$_{90}$ (h, $P > 0.05, n = 5$). All values recovered to control values after removal of heptanol from the perfusing solution ($P > 0.05$).

doi:10.1371/journal.pone.0148858.g004
increased AERP to 54.5 ± 3.1 ms (asterisk, *P* < 0.05) without altering APD$_{90}$ (25.0 ± 2.3 ms; *P* > 0.05). Activation latency, AERP and APD$_{90}$ values in both the arrhythmic and non-arrhythmic groups recovered to their baseline values after withdrawal of heptanol (*P* > 0.05).

Heptanol increases AERP/latency and AERP/APD ratios in the arrhythmic group but not in the non-arrhythmic group

In the arrhythmic group, heptanol (2 mM) increased AERP/latency ratio from 1.4 ± 0.1 to 2.1 ± 0.2 (asterisks, *P* < 0.01) and increased AERP/APD$_{90}$ ratio from 1.0 ± 0.1 to 2.1 ± 0.2 (asterisks, *P* < 0.001) (Fig 5a and 5b). Baseline characteristics were also different for these derived parameters in the non-arrhythmic group, in that it showed longer AERP/latency ratio (Fig 5c; 2.1 ± 0.3; *P* < 0.05) and higher AERP/APD ratio (Fig 5d; 2.0 ± 0.2; *P* > 0.05) compared to the initially arrhythmic group. Heptanol did not significantly alter either parameter in this group (*P* > 0.05). In both the arrhythmic and non-arrhythmic groups, AERP/latency and ERP/APD ratio recovered to their baseline values after withdrawal of heptanol.

Fig 5. Derived parameters. Heptanol (2 mM) increased excitation wavelength (a, asterisks, ANOVA, *P* < 0.01) and AERP/APD$_{90}$ ratio (b, *P* < 0.001) in the arrhythmic group, but did not alter either parameter in the non-arrhythmic group (c and d, *P* > 0.05). All values recovered to control values after removal of heptanol from the perfusing solution (*P* > 0.05).

doi:10.1371/journal.pone.0148858.g005
In a separate set of experiments, the concentration-dependence of heptanol were explored. Lower heptanol concentrations did not show any anti-arrhythmic effects, nor were any changes in CV, ERP, APD, AERP/latency and AERP/APD ratios observed (Table 1).

Taken together, the above findings demonstrate that heptanol exerted atrial anti-arrhythmic actions, in contrast with its known ventricular pro-arrhythmic effects. In both the atrial and ventricles, increased activation latency, increased ERPs and unchanged APDs were found. These differences can nevertheless be explained by increased atrial but reduced ventricular ERP/latency ratio, despite increased ERP/APD ratios in both.

Discussion

Cardiac excitation depends on an orderly activation and recovery sequences of action potentials (APs) through successive regions of the working myocardium [19]. Activation involves generation of the AP upstroke with a resulting activation latency that is inversely proportional to the conduction velocity (CV) [20]. Recovery involves both repolarisation and resumption of excitability, represented by action potential duration (APD) and effective refractory period (ERP), respectively. Disruption in the relationships between these electrophysiological parameters, for example due to reduced CVs, prolonged or shortened APDs or shortened ERPs, or combinations of such changes, can lead to both atrial and ventricular arrhythmias [21, 22]. This may be explained by a reduction in excitation wavelength given by CV x ERP, which would predispose the hearts to circus-type or spiral wave re-entry [23, 24]. In clinical electrophysiological studies, activation latency is often measured without determining the corresponding CVs (Katsiva et al., 1998). As such, excitation wavelength can be approximated using the ERP/latency ratio [25]. Alternatively, an APD/ERP ratio > 1 (i.e. a positive critical interval for re-excitation given by APD—ERP) may increase the propensity of re-excitation before full AP repolarization [26] via a phase 2 re-entrant mechanism [27] or one involving prolonged repolarization-dependent re-excitation [28].

Pharmacological methods have been used to study the mechanisms of arrhythmogenesis because these have the advantage of producing acute effects that can be reversed after drug withdrawal. For example, the lipophilic agent heptanol was used to explore the arrhythmogenic consequences of slowed AP conduction in mouse [10, 29], rat [30], rabbit [31, 32] and canine heart preparations [33]. It reduces gap junction conductance at /C20 1 mM by decreasing the

<table>
<thead>
<tr>
<th>Parameter</th>
<th>control</th>
<th>0.1</th>
<th>P</th>
<th>0.5</th>
<th>P</th>
<th>1</th>
<th>P</th>
<th>2</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>spontaneous arrhythmia</td>
<td>0 out of 11</td>
<td>0 out of 11</td>
<td>N.S.</td>
<td>0 out of 11</td>
<td>N.S.</td>
<td>0 out of 11</td>
<td>N.S.</td>
<td>0 out of 11</td>
<td>N.S.</td>
</tr>
<tr>
<td>inducible arrhythmia</td>
<td>5 out of 10</td>
<td>2 out of 10</td>
<td>N.S.</td>
<td>4 out of 10</td>
<td>N.S.</td>
<td>4 out of 10</td>
<td>N.S.</td>
<td>0 out of 10</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>APD90</td>
<td>25.2 ± 1.0</td>
<td>24.3 ± 1.6</td>
<td>N.S.</td>
<td>24.6 ± 1.3</td>
<td>N.S.</td>
<td>25.6 ± 1.1</td>
<td>N.S.</td>
<td>25.8 ± 1.8</td>
<td>N.S.</td>
</tr>
<tr>
<td>APD70</td>
<td>13.9 ± 0.5</td>
<td>12.6 ± 1.8</td>
<td>N.S.</td>
<td>13.8 ± 1.3</td>
<td>N.S.</td>
<td>15.7 ± 1.2</td>
<td>N.S.</td>
<td>14.0 ± 1.3</td>
<td>N.S.</td>
</tr>
<tr>
<td>APD50</td>
<td>8.2 ± 0.9</td>
<td>8.3 ± 1.8</td>
<td>N.S.</td>
<td>9.2 ± 1.3</td>
<td>N.S.</td>
<td>9.9 ± 1.3</td>
<td>N.S.</td>
<td>8.6 ± 1.2</td>
<td>N.S.</td>
</tr>
<tr>
<td>APD30</td>
<td>4.3 ± 0.5</td>
<td>5.2 ± 1.0</td>
<td>N.S.</td>
<td>5.8 ± 1.0</td>
<td>N.S.</td>
<td>6.6 ± 1.1</td>
<td>N.S.</td>
<td>5.6 ± 1.0</td>
<td>N.S.</td>
</tr>
<tr>
<td>activation latency</td>
<td>21.9 ± 1.3</td>
<td>23.0 ± 3.1</td>
<td>N.S.</td>
<td>21.9 ± 2.8</td>
<td>N.S.</td>
<td>23.9 ± 3.1</td>
<td>N.S.</td>
<td>29.5 ± 1.8</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>AERP</td>
<td>34.4 ± 2.8</td>
<td>32.9 ± 4.7</td>
<td>N.S.</td>
<td>39.6 ± 5.8</td>
<td>N.S.</td>
<td>41.1 ± 6.1</td>
<td>N.S.</td>
<td>60.0 ± 1.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AERP/latency ratio</td>
<td>1.6 ± 0.1</td>
<td>1.5 ± 0.1</td>
<td>N.S.</td>
<td>1.8 ± 0.2</td>
<td>N.S.</td>
<td>1.8 ± 0.2</td>
<td>N.S.</td>
<td>2.1 ± 0.2</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>AERP/APD ratio</td>
<td>1.3 ± 0.1</td>
<td>1.4 ± 0.2</td>
<td>N.S.</td>
<td>1.6 ± 0.2</td>
<td>N.S.</td>
<td>1.6 ± 0.2</td>
<td>N.S.</td>
<td>2.3 ± 0.1</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0148858.t001

Heptanol Exerts Anti-Arrhythmic Effects in the Mouse Atria
fluidity of cholesterol-rich domains in the plasma membrane [34]. It is also known to reduce sodium channel conductance ≥ 2 mM by producing both a depolarizing shift in the voltage dependence of activation and a hyperpolarizing shift in the voltage dependence of inactivation [35]. The inhibitory effects of heptanol on gap junctions and sodium channel provide an explanation for its action in reducing CV [10, 32]. Furthermore, prolongation of ERP can be explained by heptanol causing slower recovery of sodium channels from inactivation.

The present experiments proceeded to determine whether atrial properties differ from the ventricular findings both before and after heptanol treatment. There was no evidence of arrhythmias observed during regular pacing in the atria, as was the case in the ventricles in untreated hearts [10]. However, PES procedures provoked atrial tachy-arrhythmias in a subset of untreated hearts, consistent with previous observations of arrhythmia inducibility in the mouse atria [13, 14]. The arrhythmic group showed shorter activation latencies, shorter ERPs but statistically indistinguishable APDs when compared with the non-arrhythmic group. Therefore, lower ERP/latency and ERP/APD ratios were observed for the arrhythmic group, in keeping with the increased arrhythmogenicity.

It is interesting that under control conditions, there appears to be two distinct population of hearts, where one group showed an arrhythmic phenotype, whereas the other did not. Previous experiments in mouse hearts have demonstrated almost every heart showed evidence of atrial arrhythmias [13, 14]. However, the experiments described in these studies did not mention any exclusion criteria, implying that all of the hearts isolated were used for subsequent experimentation. It could very well be the case that some hearts in these experiments had endured tissue ischaemia during the isolation procedures, making the preparations more prone to arrhythmogenesis. In the present study, only the hearts that showed normal pink colouration and spontaneous ventricular activity were studied further, excluding the hearts that showed signs of myocardial damage during isolation that could have increased the baseline arrhythmogenicity under control conditions. In our previous studies, none of the hearts studied showed evidence of ventricular arrhythmias whether during regular pacing or PES [36]. The fact that atrial arrhythmias were observed in some hearts implied that the atria may be intrinsically more prone to arrhythmogenesis than the ventricles [10].

In contrast to its previously reported pro-arrhythmic ventricular effects, heptanol (2 mM) abolished these atrial arrhythmic phenomena, despite similarly increasing activation latencies and prolonging ERPs and leaving APDs unaltered in both cases. In the atria, it increased ERP/latency and ERP/APD ratios in the arrhythmic group to values that approximate those of the baseline non-arrhythmic group. Neither parameter was altered in the non-arrhythmic group with heptanol. Thus, heptanol rendered the arrhythmic hearts non-arrhythmic where their electrical properties shifted towards those of the non-arrhythmic group. Larger ERP/latency ratio would be expected to reduce circus-type or spiral wave entry, whereas increased ERP/APD ratio [37] would prevent phase 2 re-entry [38]. In the ventricles, pro-arrhythmic effects of heptanol were similarly associated with prolonged ERPs, increased activation latencies and unaltered APDs, with a resultant decrease in ERP/latency ratios despite increasing ERP/APD ratios. Moreover, the critical interval (CI) given by APD90 – ERP represents absolute time differences, rather than relative differences given by ERP/APD ratio. The CI represents the time period over which re-excitation is theoretically possible. Under control conditions, the CI was slightly negative in the arrhythmic atria and much more negative in the non-arrhythmic atria, and was also negative in the ventricles. It is therefore a poor predictor of arrhythmogenicity, because a negative interval should not be compatible with the occurrence of arrhythmias. Thus, consideration of these parameters in both atria and ventricles indicate that ERP/latency ratio appears to be the central determinant of arrhythmogenesis.
It is interesting to note that heptanol at all concentrations studied prolonged the interval between the start of atrial and the start of ventricular deflection. This would suggest heptanol exerting atrioventricular block. At the highest concentration studied of 2 mM, this block became a second degree heart block with 2:1 conduction, which rapidly progressed to third degree heart block within 90 seconds. The AV block produced by heptanol is consistent with its inhibitory effects on sodium channel and gap junction function, and the roles of these channels in normal AV conduction [39, 40].

Limitations of this study

A major limitation study is that this study provides a phenomenological description of atrial and ventricular differences but cannot provide the evidence to explain these observations. Nevertheless, there are several potential explanations for the differences between atrial and ventricular electrophysiology. This may partly be attributed to heterogeneity in sodium channels in these tissues. In atrial myocytes, $I_{Na}$ density is higher, activation and inactivation voltages are more negative, time constants for activation and inactivation are twice as rapid, and recovery from inactivation is slower when compared to ventricular myocytes [41]. The different kinetics of the sodium channel observed, in turn, could be explained by distinct $\alpha$-subunit isoforms and further modulation by $\beta$-subunits [42–44]. Furthermore, differences in gap junctions mediating intercellular coupling are observed in these chambers. Thus, the Cx43 isoform is expressed in both atrial and ventricular tissue [45], whereas Cx40 is only found in the atria and His-Purkinje system [46] and not in the ventricles [47]. These different isoforms in atrial and ventricular tissue are responsible for distinct kinetics of the gap junction channels [48]. Together, the above properties could explain the difference in atrial and ventricular electrophysiology. Heptanol also affects atrial and ventricular tissue differently, exerting opposite effects on arrhythmogenicity. However, it is not known whether the kinetics of atrial and ventricular isoforms of gap junctions are affected differently by this agent. Secondly, CV were not determined in this study, as this would require measuring the distance between the stimulating and recording electrodes, which could be crudely measured using a ruler. A better method to record use a multi-electrode array, which would allow calculation of CVs by comparing activation times of adjacent sites in the array [49–51].

Finally, there does not appear to be a 'cut-off' ERP/latency ratio for the occurrence of atrial arrhythmias, as there were overlapping values in arrhythmic and non-arrhythmic hearts. Nevertheless, a pro-arrhythmic state was associated with a shorter ERP/latency ratio and vice versa in both the atria and ventricles. The length of the mouse atria is about 3 mm [52], which should only accommodate a re-entrant circuit with a circumference of around 9 mm. This is consistent with our estimated wavelength of 6 mm (using a distance between the stimulating and recording electrodes of 3 mm), implying that circus-type is indeed possible. In mice with over-expression of TGF-β1, atrial fibrillation was associated with a shorter wavelength compared to wild-type (15 mm vs. 28 mm, respectively) [52]. However, there was accompanying selective atrial fibrosis, which would increase the heterogeneity of conduction and allow micro-re-entry that can occur in smaller areas [53]. Without data from optical mapping, it was not possible to determine the electrophysiological mechanisms underlying AT observed in this study. However, previous experiments conducted in mouse hearts in non-exercised vs exercised mice have provided much insight, demonstrating possible roles of rotor formation [51].”

These findings confirmed the original hypothesis that atrial electrophysiological and arrhythmic properties differed from their ventricular counterparts both before and after application of heptanol. These differences are summarized in Table 2, explicable by the ERP/latency ratio.
Table 2. Comparisons of atrial and ventricular arrhythmic and electrophysiological properties before and after heptanol treatment.

<table>
<thead>
<tr>
<th></th>
<th>Heptanol—ventricles</th>
<th>Heptanol—atria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spontaneous arrhythmias</strong></td>
<td>Observed during regular pacing with heptanol</td>
<td>Controls—none; heptanol—none</td>
</tr>
<tr>
<td><strong>Inducible arrhythmias</strong></td>
<td>Controls—none;</td>
<td>Controls—non-arrhythmic at baseline;</td>
</tr>
<tr>
<td></td>
<td>Heptanol—Ventricular tachy-arrhythmias</td>
<td>Heptanol did not alter inducible arrhythmogenesis</td>
</tr>
</tbody>
</table>

**Directly measured parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Heptanol—ventricles</th>
<th>Heptanol—atria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activation latency</td>
<td>↑↑</td>
<td>↑ (Note: non-arrhythmic group had significantly slower CV than arrhythmic hearts at baseline)</td>
</tr>
<tr>
<td>ERP</td>
<td>↑</td>
<td>↑ (Note: non-arrhythmic group had significantly greater ERPs than arrhythmic hearts at baseline)</td>
</tr>
<tr>
<td>APD90</td>
<td>Unchanged</td>
<td>Unchanged</td>
</tr>
</tbody>
</table>

**Derived parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Heptanol—ventricles</th>
<th>Heptanol—atria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERP/latency</td>
<td>↓</td>
<td>Unchanged (Note: [1] ERP/latency in arrhythmic group significantly less than in non-arrhythmic group at baseline; [2] heptanol increased ERP/latency in arrhythmic group to a value similar to the initially non-arrhythmic hearts)</td>
</tr>
<tr>
<td>ERP/APD90</td>
<td>↑</td>
<td>↑ (Note: ERP/APD90 starts off higher than in the arrhythmic group. It was not altered by heptanol)</td>
</tr>
</tbody>
</table>

**Reversibility**

<table>
<thead>
<tr>
<th>Concentration dependence</th>
<th>Reversible</th>
<th>Reversible</th>
<th>Reversible</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mM: pro-arrhythmic and alters EP parameters;</td>
<td>2 mM: no change in arrhythmogenicity and alters EP parameters;</td>
<td>2 mM: anti-arrhythmic and alters EP parameters;</td>
<td></td>
</tr>
<tr>
<td>0.1 to 1 mM heptanol not pro-arrhythmic, alters CV and ERP but not APD, ERP/latency or ERP/APD90;</td>
<td>0.1 to 1 mM had no effect on any of the parameters</td>
<td>0.1 to 1 mM had no effect on any of the parameters</td>
<td></td>
</tr>
</tbody>
</table>

**References**


**Supporting Information**

S1 Dataset. Excel file of dataset on the arrhythmic and non-arrhythmic hearts: activation latency, CV, AERP, APD, AERP/latency and AERP/APD ratios.

(XLSX)

**Acknowledgments**

This manuscript is based on a results Chapter of GT’s doctoral thesis.

**Author Contributions**

Conceived and designed the experiments: GT. Performed the experiments: GT. Analyzed the data: GT VT. Contributed reagents/materials/analysis tools: GT. Wrote the paper: GT VT JMY BS.


